Skip to main content

Biomarkers Market to Surpass USD 206.04 Billion by 2031 | Skyquest Technology

Written by Customer Service on . Posted in Mergers And Acquisitions.

Westford USA, July 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global biomarkers market will attain a value of USD 206.04 billion by 2031, with a CAGR of 13.3% during the forecast period (2024-2031). Factors likely to fuel the growth of the biomarkers market are the increasing significance of companion diagnostics, rising cancer prevalence, growing funding in research on biomarkers, and significant discoveries resulting from ongoing research. In diagnosing infectious diseases, biomarkers are expected to witness high growth soon. Developed biomarkers markets enable safety testing and expedite manufacturing of drugs with quicker diagnoses.

Download a detailed overview:

https://www.skyquestt.com/sample-request/biomarkers-market

Browse in-depth TOC on “Biomarkers Market”

  • Pages – 219
  • Tables – 92
  • Figures – 76

Biomarkers Market Overview:

Report Coverage Details
Market Revenue in 2023 USD 75.88 Billion
Estimated Value by 2031 USD 206.04 Billion
Growth Rate Poised to grow at a CAGR of 13.3%
Forecast Period 2024–2031
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product & Services, Type, Research Area, Technology, Disease Indication, Application, End-User, and Region
Geographies Covered North America, Europe, Asia-Pacific, Middle East & Africa, Latin America
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunities Increasing Use of Companion Diagnostics
Key Market Drivers Growing Demand for Personalized Medicine

Drug Discovery & Development Segment to Dominate the Market Due to Better Clinical Endpoints

The segment related to drug discovery and development dominated the market in 2023 driven by the utility of biomarkers in hastening drug development through better prediction of its efficacy than the conventional clinical endpoints. This predictive value is what will allow for realization of possible failures in advance, thus reducing the costs incurred during development. Hence, the leaders in this industry have worked hard on biomarkers, thereby coming up with strategic collaborations that have taken this market high.

Clinical Diagnostics is the Fastest Growing Sector Due to Ongoing Research for New Biomarkers

It is expected that the clinical diagnostics segment will grow at the maximum CAGR during this forecasted period, driven mainly by continued research in new diagnostic biomarkers. These biomarkers enable quick diagnosis and help doctors distinguish mesothelioma cancer from others. All such continuous R&D processes open doors for the discovery of even newer biomarkers against diseases like Alzheimer’s, which will further boost growth in this segment.

Technical Breakthroughs Makes North America the Leading Consumer in this Market

North America ruled the biomarkers business in 2023 with more than a 40% share of the revenue generated, which became possible due to the heavy burden of illness, enhanced consumer awareness about biomarkers, recognition of promising government initiatives, new technical breakthroughs, and enhancement in healthcare infrastructure. Other important developments include the presence of key enterprises in this area and the several organic and inorganic developments they have undertaken. These are some crucial factors projected to fuel growth in this region.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/biomarkers-market

Biomarkers Market Insights:

Drivers

  • Growing Demand for Personalized Medicine
  • Rising Need for Advanced Diagnostic Tools Driven by Chronic Disease Prevalence
  • Focus on Early Disease Detection and Prevention

Restraints

  • Rising Need for Advanced Diagnostic Tools Driven by Chronic Disease Prevalence
  • Challenges in Biomarker Validation and Standardization
  • Limited Biomarker Validation

Prominent Players in Biomarkers Market

The following are the Top Biomarkers Companies

  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc. 
  • PerkinElmer, Inc.
  • Illumina, Inc.
  • BD (Becton, Dickinson and Company)
  • Myriad Genetics, Inc.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/biomarkers-market

Key Questions Answered in Biomarkers Market Report

  • Which are Biomarkers?
  • What factors are supporting the growth of the Biomarkers Market?
  • What are the key opportunities in the Biomarkers Market?

This report provides the following insights:

  • Analysis of key drivers (growing demand for better data security, rising adoption of Blockchain and IoT technologies, increasing use of decentralized systems in different industry verticals), restraints (interoperability issues with legacy systems, complexities in integration with existing infrastructure, concerns regarding scalability of gas cleaning technologies systems), and opportunities (growing demand for data monetization, rising demand for transparent yet trusted transactions), influencing the growth of Biomarkers  market.
  • Market Penetration: All-inclusive analysis of product portfolio of different market players and status of new product launches.
  • Product Development/Innovation: Elaborate assessment of R&D activities, new product development, and upcoming trends of the Biomarkers market.
  • Market Development: Detailed analysis of potential regions where the market has potential to grow.
  • Market Diversification: Comprehensive assessment of new product launches, recent developments, and emerging regional markets.
  • Competitive Landscape: Detailed analysis of growth strategies, revenue analysis, and product innovation by new and established market players.

Related Reports:

Biosimilars Market

Proteomics Market

Genomics Market

Next Generation Sequencing Market

Cancer Diagnostics Market

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia-Pacific.

Contact:

Mr. Jagraj Singh

Skyquest Technology

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 351-333-4748

Email: sales@skyquestt.com

Visit Our Website: https://www.skyquestt.com/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.